Arkady Nekrasov
Founder of NPO Petrovax Pharm, Professor, Doctor of Chemistry, Winner of the State Prize of the Russian Federation.
- Company foundation.
- Registration of the Polyoxidonium® medicine and the Grippol® vaccine.
- Opening of the production facilities for manufacture of APIs, soft and solid dosage forms, and injectable forms.
- The beginning of the partnership with Solvay Pharma (currently, Abbott).
- Assignment of the International Non-proprietary Name - Azoximer bromide for Polyoxidonium® by WHO.
The State Prize of the Russian Federation awarded to the team of creators and developers led by Proffessor A.V. Nekrasov for the creation of innovative medicines Polyoxidonium® and Grippol® and for their implementation in healthcare practice.
- Market launch of Longidaza®.
- Opening of a modern technological manufacturing and warehouse complex in Moscow Region, complying with GMP standards.
- Market launch of the first Russian influenza vaccine Grippol® Plus in pre-filled syringes.
- Development and production of vaccines against pandemic strain of influenza A/H1N1: MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
- Annual production of Grippol® Plus vaccine for the National Immunization Schedule.
- Launch of a localization project of the 13-valent conjugate pneumococcal vaccine manufacturing (in cooperation with Pfizer).
- Obtaining EU GMP certificates (Slovakia), the beginning of export of Polyoxidonium® to the European Union.
- Petrovax becomes a part of the Interros Group.
- Market launch of Imoferaza® cosmetic cream.
- Assignment of the International Non-proprietary Name - bovhyaluronidase azoximer for Longidaza® by WHO.
- The beginning of cooperation with Boehringer Ingelheim to localize full-cycle production of innovative thrombolytic medicines Metalyse® and Actilyse®.
- Start of export of Grippol® Plus vaccine.
- Market launch of Grippol® Quadrivalent, Russian first quadrivalent inactivated subunit adjuvanted influenza vaccine.
- Expanding the portfolio with a new product - Velson® (INN: Melatonin).
- Successful completion of a post-registration study (PASS) of Polyoxidonium® in Europe (Slovakia).
- Large-scale clinical trials program for original medicinal products - Polyoxidonium® and Longidaza® - for prevention and treatment of COVID-19.
- Putting into operation the 2nd production facility for manufacturing APIs and finished dosage forms.
- Russian-Chinese project for the development and production of Convidecia vaccine for prevention of COVID-19 in cooperation with CanSino Biologics Inc.
- Market launch of new products: Uronext®, VitaFerr®, Gialera®, Whiteline® Ca+D3+K2, ARTNEO®, new dosage form - Polyoxidonium® solution.
- Charity support of the Podolsk City Hospital in equipping a COVID hospital. More than 20 thousand packages of Polyoxidonium® are donated to healthcare professionals working in the “red zones” for prevention of COVID-19.
- Obtaining a European, Indian, and American patent for Longidaza®.
- Opening of the 4th line of production for manufacturing of injectable dosage forms.
- The beginning of cooperation with ISU ABXIS (South Korea) to localize production of medicine for orphan therapy – Fabry disease.
- Charity support of the Podolsk City Hospital in equipping a COVID hospital. More than 200 thousand packages of Polyoxidonium® are donated to healthcare professionals working in the “red zones” for prevention of COVID-19 in Russian regions.
© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.